Technology
Health
Biotechnology
Enanta
$94.459876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$94.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$2.31 (2.51%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Enanta and other stocks, options, ETFs, and crypto commission-free!
About
Enanta Pharmaceuticals, Inc. Common Stock, also called Enanta, is a research and development-focused biotechnology company. Read More It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. Its brands include Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
CEO
Employees
113
Headquarters
Watertown, Massachusetts
Founded
1995
Market Cap
1.86B
Price-Earnings Ratio
25.38
Dividend Yield
0.00
Average Volume
257.67K
High Today
$96.46
Low Today
$91.86
Open Price
$92.66
Volume
51.30K
52 Week High
$127.77
52 Week Low
$64.09
Collections
Technology
Health
Biotechnology
Research And Development
2013 IPO
US
North America
News
Seeking AlphaMay 18
Enanta And EDP-305 In NASH: An Update
The obvious question is the potential issue of tolerability and adverse events which have been associated with the clinical benefits of prototype FXR agonist, Obeticholic acid.
TradingNewsNowMay 9
Present Trend: Enanta Pharmaceuticals (NASDAQ: ENTA)
Enanta Pharmaceuticals is part of the healthcare sector and is part of the biotechnology industry. The company CEO is Jay R. Luly. Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach and drug discovery capabilities to develop its products. Previous Intraday Trading Performance: The ENTA stock showed a previous change of 3.76% with an open at 88.11 and a close of 90...
Seeking AlphaMay 7
Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q2 2019 Results - Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2019 Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Carol Miceli - Director of Investor Relations Jay Luly - President & Chief Executive Officer Paul Mellett - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Paul O'Brien - Roth Capital Eric Joseph - JPMorgan Jay Olson - Oppenheimer Jack Allen - Baird Patrick Trucchio - Berenberg Capital Markets. Operator Good afternoon. My name is Jesse...
Price Paid on Robinhood
17% Higher
Right Now
52 Week Low
$64.09
Average Price Paid
$80.68
52 Week High
$127.77
Earnings
-$0.06
$0.67
$1.40
$2.13
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Available Aug 6, After Hours